S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:MRVI

Maravai LifeSciences (MRVI) Stock Price, News & Analysis

$8.58
+0.24 (+2.88%)
(As of 03/27/2024 ET)
Today's Range
$8.26
$8.63
50-Day Range
$5.11
$8.76
52-Week Range
$4.52
$16.62
Volume
1.86 million shs
Average Volume
2.60 million shs
Market Capitalization
$2.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.13

Maravai LifeSciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
29.7% Upside
$11.13 Price Target
Short Interest
Bearish
6.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
1.25mentions of Maravai LifeSciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.15) to ($0.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.79 out of 5 stars

Medical Sector

234th out of 939 stocks

Pharmaceutical Preparations Industry

101st out of 435 stocks

MRVI stock logo

About Maravai LifeSciences Stock (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

MRVI Stock Price History

MRVI Stock News Headlines

Should You Sell Maravai LifeSciences (MRVI)?
The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
MRVI Apr 2024 2.500 call
MRVI Apr 2024 2.500 put
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
Maravai LifeSciences Shares Rise 65% After 4Q Results
MRVI Jan 2025 5.000 call
MRVI Jan 2025 10.000 put
MRVI Sep 2024 5.000 call
MRVI Jun 2024 15.000 call
Maravai LifeSciences Holdings Inc.
Maravai Lifesciences Holdings Inc (MRVI)
See More Headlines
Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRVI
Fax
N/A
Employees
650
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.13
High Stock Price Target
$17.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+29.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-119,030,000.00
Pretax Margin
213.79%

Debt

Sales & Book Value

Annual Sales
$288.95 million
Cash Flow
$0.10 per share
Book Value
$3.14 per share

Miscellaneous

Free Float
250,847,000
Market Cap
$2.16 billion
Optionable
Optionable
Beta
-0.02
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Carl W. Hull (Age 65)
    Co-Founder & Executive Chairman
    Comp: $1.45M
  • Mr. William E. Martin III (Age 48)
    Chief Executive Officer
    Comp: $2.07M
  • Mr. Kevin M. Herde (Age 52)
    Executive VP & CFO
    Comp: $778.28k
  • Dr. Peter Michael Leddy Ph.D. (Age 61)
    Executive VP & Chief Administrative Officer
    Comp: $757k
  • Ms. Christine Dolan (Age 56)
    Executive Vice President of Biologics Safety Testing
    Comp: $755.97k
  • Ms. Debra Hart
    Senior Director of Investor Relations
  • Mr. Kurt Oreshack (Age 43)
    Executive VP, General Counsel & Secretary
    Comp: $701.4k
  • Ms. Becky Buzzeo
    Executive VP & Chief Commercial Officer
  • Dr. Kate E. Broderick Ph.D.
    Chief Innovation Officer
  • Mr. Christopher Benoit
    Executive Vice President of Enzymes

MRVI Stock Analysis - Frequently Asked Questions

Should I buy or sell Maravai LifeSciences stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRVI shares.
View MRVI analyst ratings
or view top-rated stocks.

What is Maravai LifeSciences' stock price target for 2024?

9 analysts have issued 1 year price targets for Maravai LifeSciences' shares. Their MRVI share price targets range from $7.00 to $17.00. On average, they predict the company's share price to reach $11.13 in the next twelve months. This suggests a possible upside of 29.7% from the stock's current price.
View analysts price targets for MRVI
or view top-rated stocks among Wall Street analysts.

How have MRVI shares performed in 2024?

Maravai LifeSciences' stock was trading at $6.55 at the beginning of the year. Since then, MRVI stock has increased by 31.0% and is now trading at $8.58.
View the best growth stocks for 2024 here
.

When is Maravai LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our MRVI earnings forecast
.

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) released its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.01. The business earned $74.14 million during the quarter, compared to analysts' expectations of $62.99 million. Maravai LifeSciences had a negative net margin of 41.19% and a negative trailing twelve-month return on equity of 1.31%.

What ETFs hold Maravai LifeSciences' stock?
What guidance has Maravai LifeSciences issued on next quarter's earnings?

Maravai LifeSciences updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $265.0 million-$285.0 million, compared to the consensus revenue estimate of $261.0 million.

When did Maravai LifeSciences IPO?

Maravai LifeSciences (MRVI) raised $1.3 billion in an IPO on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Who are Maravai LifeSciences' major shareholders?

Maravai LifeSciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.98%), Vanguard Group Inc. (3.98%), Massachusetts Financial Services Co. MA (2.39%), Mackenzie Financial Corp (2.06%), Braidwell LP (2.01%) and Pacer Advisors Inc. (1.18%).

How do I buy shares of Maravai LifeSciences?

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRVI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners